ArticleTissue engineering. Part A2020
Repairing Volumetric Muscle Loss in the Ovine Peroneus Tertius Following a 3-Month Recovery.
Article in Tissue engineering. Part A, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Impact of Passaging Primary Skeletal Muscle Cell Isolates on the Engineering of Skeletal Muscle.Tissue engineering. Part A · 2025Article
- Engineering large-scale hiPSC-derived vessel-integrated muscle-like lattices for enhanced volumetric muscle regeneration.Trends in biotechnology · 2024Article
- A Novel Minimally Invasive Surgically Induced Skeletal Muscle Injury Model in Sheep.International journal of molecular sciences · 2024Article
- Impact of Human Recombinant Irisin on Tissue-Engineered Skeletal Muscle Structure and Function.Tissue engineering. Part A · 2024Article
- Actuated tissue engineered muscle grafts restore functional mobility after volumetric muscle loss.Biomaterials · 2023Article
- Scalable macroporous hydrogels enhance stem cell treatment of volumetric muscle loss.Biomaterials · 2022Article
- Translating musculoskeletal bioengineering into tissue regeneration therapies.Science translational medicine · 2022Review
- Repairing Volumetric Muscle Loss in the Ovine Peroneus Tertius Following a 6-Month Recovery.Tissue engineering. Part A · 2022Article
- Impact of Cell Seeding Density and Cell Confluence on Human Tissue Engineered Skeletal Muscle.Tissue engineering. Part A · 2022Article
- Human muscle in gene edited pigs for treatment of volumetric muscle loss.Frontiers in genetics · 2022Review
- The War after War: Volumetric Muscle Loss Incidence, Implication, Current Therapies and Emerging Reconstructive Strategies, a Comprehensive Review.Biomedicines · 2021Review
- The Effects of Engineered Skeletal Muscle on Volumetric Muscle Loss in The Tibialis Anterior Of Rat After Three MonthsRegenerative engineering and translational medicine · 2020Article
- Next Stage Approach to Tissue Engineering Skeletal Muscle.Bioengineering (Basel, Switzerland) · 2020Review
- Recent Trends in Injury Models to Study Skeletal Muscle Regeneration and Repair.Bioengineering (Basel, Switzerland) · 2020Review
- A tissue engineering approach for repairing craniofacial volumetric muscle loss in a sheep following a 2, 4, and 6-month recovery.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Much effort has been made to fabricate engineered tissues on a scale that is clinically relevant to humans; however, scale-up remains one of the most significant technological challenges of tissue engineering to date. To address this limitation, our laboratory has developed tissue-engineered skeletal muscle units (SMUs) and engineered neural conduits (ENCs), and modularly scaled them to clinically relevant sizes for the treatment of volumetric muscle loss (VML). The goal of this study was to evaluate the SMUs and ENCs
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.